查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1662732

2030 年神經病變疼痛市場預測：按藥物類別、適應症、患者類型、給藥途徑、分銷管道和地區進行的全球分析

Neuropathic Pain Market Forecasts to 2030 - Global Analysis By Drug Class (Antidepressants, Anticonvulsant, Opioids, Capsaicin, Steroids and Other Drug Classes), Indication, Patient Type, Route of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球神經病變疼痛市場預計在 2024 年達到 82.4 億美元，預計到 2030 年將達到 143.5 億美元，預測期內的複合年成長率為 9.7%。

神經病變疼痛是一種因神經系統損傷或功能障礙而導致的複雜慢性疼痛疾病。糖尿病、帶狀皰疹、多發性硬化症和神經損傷是一些經常引起神經性疼痛的疾病。這種疼痛可能伴隨對觸覺和溫度變化的敏感性，並可能以灼熱、刺痛、麻刺或麻木感為特徵。它可能很難治療，需要多管齊下的策略，包括藥物治療、物理治療、神經阻斷和諮詢。此外，由於疾病嚴重影響患者的生活品質，因此早期診斷和有效治療對於改善患者預後至關重要。

根據美國美國衛生研究院在 PubMed Central 上發表的敘述性評論，神經病變疼痛影響約 7-10% 的一般人群。

神經病變疾病呈上升趨勢

神經病變疼痛通常與糖尿病、帶狀皰疹後遺症神經痛、多發性硬化症和創傷性神經損傷等潛在疾病有關。例如，研究表明，大約 50% 的糖尿病患者最終會發展為糖尿病神經病變，這是導致全球糖尿病發病率上升的一個主要因素。此外，老化社會容易出現神經退化，增加神經病變疾病等與老齡化相關的疾病的盛行率。由於這些病症的盛行率不斷上升，對有效的疼痛管理治療的需求也隨之增加。隨著患有神經病變疼痛的人數增加，治療方法和診斷設備的市場也預計將成長。

缺乏有效治療方法

人們仍然迫切需要改進的、長期的、真正有效的神經病變疼痛治療​​治療方法。目前可用的許多治療方法只能提供部分緩解，有些還會引起不良的副作用，例如疲勞、頭暈和消化器官系統問題。例如，雖然鴉片類藥物可用於治療急性疼痛，但由於成癮和依賴的風險較高，其在治療慢性疼痛方面的應用受到限制。此外，有些患者對常見的合併用藥沒有反應，這使得尋找正確的治療方法既費時又令人沮喪。

個性化醫療的演變

個人化醫療趨勢是神經性疼痛市場最令人興奮的前景之一。隨著研究的進展，我們對導致神經性疼痛的遺傳、分子和環境因素有了更好的了解。根據患者的基因特徵、疼痛途徑和藥物治療反應進行個人化治療可以實現更有效、更有針對性的疼痛緩解，且副作用更少。此外，該公司已經開始研究基因標記來預測患者對某些神經病變疼痛藥物的反應。該策略有可能顯著提高治療成功率，減少試驗，並為患者提供更個人化的疼痛管理選擇。

學名藥的激烈競爭

神經病變疼痛市場正受到學名藥出現的嚴重威脅。目前，許多用於治療神經病變疼痛的藥物都有學名藥，包括Duloxetine、Pregabalin和Gabapentin。學名藥通常比品牌藥便宜得多，大大減少了開發專有配方的公司的獲利機會。由於學名藥的激烈競爭，製藥公司被迫降價，這可能會降低利潤率。此外，隨著神經病變止痛藥專利到期到期，學名藥將進入市場，價格競爭可能會更加激烈。

COVID-19 的影響

COVID-19 疫情對神經性疼痛市場產生了顯著影響，既有正面的，也有負面的。由於醫院和診所將資源集中在治療新冠肺炎患者上，全球衛生危機導致衛生系統中斷，包括神經病變疼痛的診斷和治療延遲。常規預約和選擇性手術被推遲，導致患者錯過了專門的疼痛管理治療。疫情引發的經濟景氣衰退所帶來的財務限制也使患者難以支付醫療費用，尤其是那些需要先進療法和手術的患者。

糖尿病神經病變領域預計將在預測期內成長至最大的領域

預計預測期內糖尿病神經病變部分將佔據最大的市場佔有率。這種優點是由於全球糖尿病盛行率高，導致大量人罹患糖尿病神經病變。例如，國際糖尿病聯盟（IDF）預測，到2022年，20歲至79歲的成年人將有6.43億人罹患糖尿病，到2030年，這一數字將上升到7.83億人。此外，大量的糖尿病患者加強了該領域的市場佔有率，增加了對糖尿病神經病變有效治療的需求。

預計預測期內成人市場將達到最高的複合年成長率。

預計在預測期內成人市場將呈現最高的成長率。這種成長的主要原因是成人帶狀皰疹後遺症神經痛和糖尿病神經病變等疾病的發生率不斷增加。例如，國際糖尿病聯盟（IDF）預測，到2022年，20歲至79歲的成年人將有6.43億人罹患糖尿病，到2030年，這一數字將上升到7.83億人。此外，大量的糖尿病患者對糖尿病神經病變的有效治療的需求也隨之增加，從而加強了該領域的市場佔有率。

比最大的地區

預計預測期內北美地區將佔據最大的市場佔有率。造成這種優越性的主要原因是成人常見的神經病變疾病的發生率較高，例如糖尿病性神經病變、帶狀皰疹後遺症神經痛、化療引起的周邊神經病變。醫療保健基礎設施的完善以及治療意識和治療選擇機會的增加也顯著影響著該領域的市場發展。此外，由於糖尿病等慢性疾病患者數量的增加以及新的疼痛管理治療方法的持續研發，北美在市場中佔據領先地位。

複合年成長率最高的地區

預計預測期內亞太地區將呈現最高的複合年成長率。糖尿病神經病變和其他神經病變疾病的盛行率不斷上升，以及該地區醫療保健基礎設施和醫療服務機會的改善，是這種快速成長的主要原因。人們對神經病變疼痛及其可用治療方法的認知不斷提高，以及中國和印度等國家經濟狀況和醫療支出的改善，也推動了對有效疼痛管理治療的需求。此外，這些因素正在推動未來幾年亞太地區強勁的成長預測。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球神經病變疼痛市場（依藥物類別）

  • 介紹
  • 抗憂鬱症
    • 三環抗憂鬱藥物
    • 血清素-正腎上腺素再回收抑制劑(SNRI)
  • 抗驚厥藥
  • 鴉片類藥物
  • 辣椒素
  • 類固醇
  • 其他

6. 全球神經病變疼痛市場（依適應症分類）

  • 介紹
  • 糖尿病神經病變
  • 脊椎狹窄
  • 帶狀皰疹後遺症神經痛
  • 化療引起的周邊神經病變
  • 其他

7. 全球神經病變疼痛市場（依患者型態）

  • 介紹
  • 成人
  • 老年人
  • 孩子們

8. 全球神經病變疼痛市場依給藥途徑分類

  • 介紹
  • 口服
  • 經皮
  • 靜脈
  • 局部的

9. 全球神經病變疼痛市場（依分銷管道）

  • 介紹
  • 醫院藥房
  • 零售藥局
  • 網路藥局

10. 全球神經病變疼痛市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Abbott Laboratories
  • Pfizer, Inc
  • Sanofi SA
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Teva Pharmaceutical Industries Ltd.
  • Baxter Healthcare Corporation
  • Collegium Pharmaceutical, Inc.
  • Mallinckrodt Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd
  • Glenmark Pharmaceuticals Limited
  • Bristol-Myers Squibb Company
  • Grunenthal GmbH
Product Code: SMRC28593

According to Stratistics MRC, the Global Neuropathic Pain Market is accounted for $8.24 billion in 2024 and is expected to reach $14.35 billion by 2030 growing at a CAGR of 9.7% during the forecast period. Neuropathic pain is a complex, chronic pain condition that arises due to damage or dysfunction in the nervous system. Diabetes, shingles, multiple sclerosis, and nerve injuries are among the conditions that frequently cause it. This kind of pain can be accompanied by hypersensitivity to touch or temperature changes and is typified by feelings of burning, stabbing, tingling, or numbness. It can be difficult to treat, necessitating a multimodal strategy that may involve drugs, physical therapy, nerve blocks, and counselling. Moreover, a person's quality of life is greatly impacted by the condition, so improving patient outcomes requires early diagnosis and efficient treatment.

According to a narrative review published in the National Institutes of Health's PubMed Central, neuropathic pain does indeed affect approximately 7-10% of the general population.

Market Dynamics:

Driver:

Growing number of neuropathic disorders

Neuropathic pain is often associated with underlying conditions such as diabetes, post-herpetic neuralgia, multiple sclerosis, and traumatic nerve injuries. For instance, studies indicate that about 50% of individuals with diabetes will eventually develop diabetic neuropathy, making the global increase in diabetes a major contributing factor. Furthermore, nerve degeneration is more likely to occur in an aging population, which increases the prevalence of age-related disorders like neuropathy. The need for efficient pain management treatments is fueled by the increasing prevalence of these illnesses. The market for therapies and diagnostic equipment is anticipated to expand in tandem with the rise in the number of people experiencing neuropathic pain.

Restraint:

Absence of effective treatment choices

Even with improvements in neuropathic pain management, there is still a big need for long-term, really effective therapies. Many of the treatments available today only offer partial relief, and some have unfavorable side effects like fatigue, lightheadedness, or digestive problems. For instance, opioid drugs are useful for treating acute pain, but their use in treating chronic pain is restricted due to their high potential for addiction and dependency. Additionally, some patients might not respond to commonly prescribed medications, which can cause frustration and delay in locating an appropriate course of treatment.

Opportunity:

Evolution of personalized medicine

The trend toward personalized medicine is one of the most exciting prospects in the market for neuropathic pain. The genetic, molecular, and environmental factors that contribute to neuropathic pain are becoming better understood as research progresses. More effective and targeted pain relief with fewer side effects may be possible with personalized treatments based on a patient's genetic profile, pain pathways, and reaction to medication. Moreover, businesses are already looking into genetic markers to forecast a patient's reaction to particular neuropathic painkillers. This strategy could significantly increase treatment success rates, cut down on trial and error, and provide patients with more individualized pain management options, making it a very profitable area for innovation.

Threat:

Vigorous competition from generic medicines

The market for neuropathic pain is seriously threatened by the availability of generic medications. There are now generic versions of many drugs used to treat neuropathic pain, including duloxetine, pregabalin, and gabapentin. Since generic medications are usually far less expensive than their branded equivalents, businesses that have created unique formulations have a much smaller chance of making money. Pharmaceutical companies are under pressure to cut prices due to the fierce competition from generics, which can reduce profit margins. Additionally, this price competition will also get more intense as generic versions of neuropathic painkillers continue to hit the market as more patents for these drugs expire.

Covid-19 Impact:

The market for neuropathic pain was significantly impacted by the COVID-19 pandemic, both positively and negatively. As hospitals and clinics concentrated their resources on treating COVID-19 cases, the global healthcare crisis caused disruptions in healthcare systems, including delays in the diagnosis and treatment of neuropathic pain. Patients had less access to specialized pain management therapies as a result of routine appointments and elective procedures being delayed. Financial limitations brought on by the pandemic's economic downturn also made it harder for patients to pay for treatments, particularly those that required sophisticated therapies or procedures.

The Diabetic Neuropathy segment is expected to be the largest during the forecast period

The Diabetic Neuropathy segment is expected to account for the largest market share during the forecast period. This dominance is explained by the high global prevalence of diabetes, which causes diabetic neuropathy in a considerable number of people. The International Diabetes Federation (IDF), for example, projected that by 2022, 643 million adults between the ages of 20 and 79 would have diabetes by 2030, and by 2045, that number would have increased to 783 million. Moreover, the market share of this segment is strengthened by the large number of diabetics, which raises the need for efficient treatments for diabetic neuropathy.

The Adult segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Adult segment is predicted to witness the highest growth rate. The main cause of this growth is the rising incidence of diseases like postherpetic neuralgia and diabetic neuropathy in adults. The International Diabetes Federation (IDF), for example, projected that by 2022, 643 million adults between the ages of 20 and 79 would have diabetes by 2030, and by 2045, that number would have increased to 783 million. Additionally, the market share of this segment is strengthened by the large number of diabetics, which raises the need for efficient treatments for diabetic neuropathy.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. The main cause of this dominance is the high frequency of neuropathic conditions that are more common in adults, such as diabetic neuropathy, post herpetic neuralgia, and chemotherapy-induced peripheral neuropathy. The development of the market in this area is also greatly influenced by the existence of sophisticated healthcare infrastructure, as well as by greater awareness of and access to treatment options. Furthermore, North America leads the market due to the growing number of people with chronic illnesses like diabetes and the continuous research and development of new pain management treatments.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR. The increasing prevalence of diabetic neuropathy and other neuropathic conditions, as well as the region's growing healthcare infrastructure and improved access to healthcare, are the main causes of this rapid growth. The need for efficient pain management treatments is also being fueled by rising awareness of neuropathic pain and its available treatments, as well as bettering economic conditions and healthcare spending in nations like China and India. Moreover, the strong growth prediction for the APAC region in the upcoming years is influenced by these factors.

Key players in the market

Some of the key players in Neuropathic Pain market include Abbott Laboratories, Pfizer, Inc, Sanofi S.A., Johnson & Johnson Services, Inc., Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Baxter Healthcare Corporation, Collegium Pharmaceutical, Inc., Mallinckrodt Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Limited, Bristol-Myers Squibb Company and Grunenthal GmbH.

Key Developments:

In December 2024, Teva Pharmaceutical Industries Ltd. announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.

In September 2024, Abbott India Limited has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company Limited to market and distribute "Vonoprazan" in India under the brand name "Vonefi". Vonoprazan addresses severe acid related disorders like reflux esophagitis through a once daily dose.

In August 2024, Johnson & Johnson1 announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of $600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion.

Drug Classes Covered:

  • Antidepressants
  • Anticonvulsant
  • Opioids
  • Capsaicin
  • Steroids
  • Other Drug Classes

Indications Covered:

  • Diabetic Neuropathy
  • Spinal Stenosis
  • Post-Herpetic Neuralgia
  • Chemotherapy-Induced Peripheral Neuropathy
  • Other Indications

Patient Types Covered:

  • Adult
  • Geriatric
  • Pediatric

Route of Administrations Covered:

  • Oral
  • Transdermal
  • Intravenous
  • Topical

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neuropathic Pain Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Antidepressants
    • 5.2.1 Tricyclic Antidepressants
    • 5.2.2 Serotonin-Noradrenaline Reuptake Inhibitors (SNRI)
  • 5.3 Anticonvulsant
  • 5.4 Opioids
  • 5.5 Capsaicin
  • 5.6 Steroids
  • 5.7 Other Drug Classes

6 Global Neuropathic Pain Market, By Indication

  • 6.1 Introduction
  • 6.2 Diabetic Neuropathy
  • 6.3 Spinal Stenosis
  • 6.4 Post-Herpetic Neuralgia
  • 6.5 Chemotherapy-Induced Peripheral Neuropathy
  • 6.6 Other Indications

7 Global Neuropathic Pain Market, By Patient Type

  • 7.1 Introduction
  • 7.2 Adult
  • 7.3 Geriatric
  • 7.4 Pediatric

8 Global Neuropathic Pain Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Transdermal
  • 8.4 Intravenous
  • 8.5 Topical

9 Global Neuropathic Pain Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacy
  • 9.3 Retail Pharmacy
  • 9.4 Online Pharmacy

10 Global Neuropathic Pain Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 Pfizer, Inc
  • 12.3 Sanofi S.A.
  • 12.4 Johnson & Johnson Services, Inc.
  • 12.5 Novartis AG
  • 12.6 Eli Lilly and Company
  • 12.7 GlaxoSmithKline PLC
  • 12.8 Teva Pharmaceutical Industries Ltd.
  • 12.9 Baxter Healthcare Corporation
  • 12.10 Collegium Pharmaceutical, Inc.
  • 12.11 Mallinckrodt Pharmaceuticals
  • 12.12 Sun Pharmaceutical Industries Ltd
  • 12.13 Glenmark Pharmaceuticals Limited
  • 12.14 Bristol-Myers Squibb Company
  • 12.15 Grunenthal GmbH

List of Tables

  • Table 1 Global Neuropathic Pain Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Neuropathic Pain Market Outlook, By Drug Class (2022-2030) ($MN)
  • Table 3 Global Neuropathic Pain Market Outlook, By Antidepressants (2022-2030) ($MN)
  • Table 4 Global Neuropathic Pain Market Outlook, By Tricyclic Antidepressants (2022-2030) ($MN)
  • Table 5 Global Neuropathic Pain Market Outlook, By Serotonin-Noradrenaline Reuptake Inhibitors (SNRI) (2022-2030) ($MN)
  • Table 6 Global Neuropathic Pain Market Outlook, By Anticonvulsant (2022-2030) ($MN)
  • Table 7 Global Neuropathic Pain Market Outlook, By Opioids (2022-2030) ($MN)
  • Table 8 Global Neuropathic Pain Market Outlook, By Capsaicin (2022-2030) ($MN)
  • Table 9 Global Neuropathic Pain Market Outlook, By Steroids (2022-2030) ($MN)
  • Table 10 Global Neuropathic Pain Market Outlook, By Other Drug Classes (2022-2030) ($MN)
  • Table 11 Global Neuropathic Pain Market Outlook, By Indication (2022-2030) ($MN)
  • Table 12 Global Neuropathic Pain Market Outlook, By Diabetic Neuropathy (2022-2030) ($MN)
  • Table 13 Global Neuropathic Pain Market Outlook, By Spinal Stenosis (2022-2030) ($MN)
  • Table 14 Global Neuropathic Pain Market Outlook, By Post-Herpetic Neuralgia (2022-2030) ($MN)
  • Table 15 Global Neuropathic Pain Market Outlook, By Chemotherapy-Induced Peripheral Neuropathy (2022-2030) ($MN)
  • Table 16 Global Neuropathic Pain Market Outlook, By Other Indications (2022-2030) ($MN)
  • Table 17 Global Neuropathic Pain Market Outlook, By Patient Type (2022-2030) ($MN)
  • Table 18 Global Neuropathic Pain Market Outlook, By Adult (2022-2030) ($MN)
  • Table 19 Global Neuropathic Pain Market Outlook, By Geriatric (2022-2030) ($MN)
  • Table 20 Global Neuropathic Pain Market Outlook, By Pediatric (2022-2030) ($MN)
  • Table 21 Global Neuropathic Pain Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 22 Global Neuropathic Pain Market Outlook, By Oral (2022-2030) ($MN)
  • Table 23 Global Neuropathic Pain Market Outlook, By Transdermal (2022-2030) ($MN)
  • Table 24 Global Neuropathic Pain Market Outlook, By Intravenous (2022-2030) ($MN)
  • Table 25 Global Neuropathic Pain Market Outlook, By Topical (2022-2030) ($MN)
  • Table 26 Global Neuropathic Pain Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 27 Global Neuropathic Pain Market Outlook, By Hospital Pharmacy (2022-2030) ($MN)
  • Table 28 Global Neuropathic Pain Market Outlook, By Retail Pharmacy (2022-2030) ($MN)
  • Table 29 Global Neuropathic Pain Market Outlook, By Online Pharmacy (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.